Bemdaneprocel Enters Phase 3 Trial as Investigational Stem Cell Therapy for Parkinson’s Disease
Bayer AG and BlueRock Therapeutics have announced details of a Phase 3 registrational trial, exPDite-2, to evaluate the efficacy and safety of bemdaneprocel in Parkinson’s disease. The study, set to begin in 2025, builds on prior Phase 1 data and will assess improvements in ON time without troublesome dyskinesia over 78 weeks.
